Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus

BACKGROUND: We explore the dose–efficacy relationship of lenvatinib plus anti-PD-1 in patients with unresectable hepatocellular carcinoma (u-HCC) infected with hepatitis B virus (HBV) in real-world practice. Furthermore, we identify the population sensitive to lenvatinib plus anti-PD-1 treatments. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Xiujuan, Yu, Shumin, Pang, Jianzhi, Zhang, Wei, Kong, Huifang, Huang, Jiagan, Zhang, Guojie, Zhang, Huixin, Gu, Yueyue, Chen, Yan, Yang, Bin, Liu, Jingping, Zeng, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257432/
https://www.ncbi.nlm.nih.gov/pubmed/37304208
http://dx.doi.org/10.2147/JHC.S411748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257432/
https://www.ncbi.nlm.nih.gov/pubmed/37304208
http://dx.doi.org/10.2147/JHC.S411748

Ejemplares similares